Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Steady Medical (300888) as of February 25, 2026, with a closing price of 35.49 yuan, reflecting a 1.31% increase [1] - The company reported a main revenue of 7.897 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 30.1%, and a net profit attributable to shareholders of 732 million yuan, up 32.36% year-on-year [2] - In Q3 2025, the company achieved a single-quarter main revenue of 2.601 billion yuan, a 27.71% increase year-on-year, and a net profit of 240 million yuan, which is a 42.11% increase year-on-year [2] Group 2 - The company has a debt ratio of 33.87% and reported investment income of 33.23 million yuan, with financial expenses of -2.036 million yuan, and a gross profit margin of 48.32% [2] - Over the past 90 days, five institutions have provided ratings for the stock, with four buy ratings and one hold rating, and the average target price set by institutions is 5.207 billion yuan [2]

Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Steady Medical (300888) as of February 24, 2026, with a closing price of 35.03 yuan, reflecting a 1.01% increase [1] - The company reported a main revenue of 7.897 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 30.1%, and a net profit attributable to shareholders of 732 million yuan, up 32.36% year-on-year [2] - In the third quarter of 2025, the company achieved a single-quarter main revenue of 2.601 billion yuan, a 27.71% increase year-on-year, and a net profit of 240 million yuan, which is a 42.11% increase year-on-year [2] Group 2 - The company has a debt ratio of 33.87% and reported investment income of 33.23 million yuan, with financial expenses of -2.036 million yuan, and a gross profit margin of 48.32% [2] - Over the past 90 days, five institutions have provided ratings for the stock, with four buy ratings and one hold rating, and the average target price set by institutions is 5.207 billion yuan [2] - The main business of Steady Medical includes the research, production, and sales of cotton products, covering medical health, personal care, family care, maternal and infant care, and home textiles [2]

Core Viewpoint - The financial performance of Steady Medical (300888) shows significant growth in revenue and net profit for the first three quarters of 2025, indicating a strong operational performance in the medical and personal care sectors [2]. Financial Performance - For the first three quarters of 2025, Steady Medical reported a main revenue of 7.897 billion yuan, an increase of 30.1% year-on-year [2]. - The net profit attributable to shareholders reached 732 million yuan, up 32.36% year-on-year [2]. - The net profit after deducting non-recurring items was 679 million yuan, reflecting a 43.93% increase year-on-year [2]. - In Q3 2025 alone, the company achieved a main revenue of 2.601 billion yuan, a year-on-year increase of 27.71% [2]. - The net profit for Q3 2025 was 240 million yuan, up 42.11% year-on-year [2]. - The net profit after deducting non-recurring items for Q3 was 218 million yuan, marking a 50.77% increase year-on-year [2]. - The company's debt ratio stands at 33.87%, with investment income of 33.23 million yuan and financial expenses of -2.036 million yuan [2]. - The gross profit margin is reported at 48.32% [2]. Market Activity - As of February 11, 2026, Steady Medical's stock closed at 35.39 yuan, with a slight decrease of 0.03% [1]. - The trading volume was 19,200 hands, with a total transaction amount of 68.0836 million yuan [1]. - The net outflow of main funds was 13.0146 million yuan, accounting for 19.12% of the total transaction amount [1]. - Retail investors showed a net inflow of 13.4785 million yuan, representing 19.8% of the total transaction amount [1]. Analyst Ratings - In the last 90 days, 8 institutions have provided ratings for Steady Medical, with 7 buy ratings and 1 hold rating [2]. - The average target price set by institutions over the past 90 days is 5.451 billion yuan [2].

Core Viewpoint - The company Steady Medical (300888) has shown significant growth in its financial performance for the first three quarters of 2025, with a notable increase in both revenue and net profit compared to the previous year [2]. Financial Performance - For the first three quarters of 2025, Steady Medical reported a total revenue of 7.897 billion yuan, representing a year-on-year increase of 30.1% [2]. - The net profit attributable to shareholders reached 732 million yuan, up 32.36% year-on-year [2]. - The company's net profit excluding non-recurring items was 679 million yuan, reflecting a 43.93% increase year-on-year [2]. - In the third quarter of 2025 alone, the company achieved a revenue of 2.601 billion yuan, which is a 27.71% increase compared to the same quarter last year [2]. - The net profit for the third quarter was 240 million yuan, marking a 42.11% year-on-year growth [2]. - The net profit excluding non-recurring items for the third quarter was 218 million yuan, showing a 50.77% increase year-on-year [2]. - The company's debt ratio stands at 33.87%, with investment income of 33.23 million yuan and financial expenses of -2.036 million yuan [2]. - The gross profit margin is reported at 48.32% [2]. Market Activity - As of February 9, 2026, Steady Medical's stock closed at 35.71 yuan, with a turnover rate of 0.57% and a trading volume of 33,400 hands, resulting in a transaction amount of 119 million yuan [1]. - On February 9, the net outflow of main funds was 8.6952 million yuan, accounting for 7.29% of the total transaction amount, while retail investors saw a net inflow of 15.475 million yuan, representing 12.97% of the total transaction amount [1]. Analyst Ratings - In the last 90 days, 10 institutions have provided ratings for Steady Medical, with 8 giving a "buy" rating and 2 giving a "hold" rating [2]. - The average target price set by institutions over the past 90 days is 5.451 billion yuan [2].

Group 1 - The core viewpoint of the news is that Steady Medical (300888) has shown significant growth in its financial performance, with a notable increase in revenue and net profit for the first three quarters of 2025 compared to the previous year [2] - As of February 5, 2026, Steady Medical's stock closed at 35.87 yuan, reflecting a 0.82% increase, with a trading volume of 41,100 hands and a total transaction amount of 148 million yuan [1] - The company reported a main business revenue of 7.32 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 30.1%, and a net profit attributable to shareholders of 732 million yuan, up 32.36% year-on-year [2] Group 2 - In the third quarter of 2025, the company achieved a single-quarter main business revenue of 2.6 billion yuan, which is a 27.71% increase year-on-year, and a net profit of 240 million yuan, reflecting a 42.11% year-on-year growth [2] - The company has a debt ratio of 33.87% and reported an investment income of 33.23 million yuan, with financial expenses of -2.036 million yuan and a gross profit margin of 48.32% [2] - Over the past 90 days, 11 institutions have rated the stock, with 9 buy ratings and 2 hold ratings, and the average target price set by institutions is 54.51 yuan [2]

Group 1 - The core viewpoint of the news is that Steady Medical (300888) has shown significant growth in its financial performance, with a notable increase in revenue and net profit for the first three quarters of 2025 compared to the previous year [2] - As of January 27, 2026, Steady Medical's stock closed at 37.0 yuan, reflecting a decrease of 1.62% with a trading volume of 60,000 hands and a transaction amount of 221 million yuan [1] - The company reported a main business revenue of 7.32 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 30.1%, and a net profit attributable to shareholders of 732 million yuan, up 32.36% year-on-year [2] Group 2 - In the third quarter of 2025, the company achieved a single-quarter main business revenue of 2.6 billion yuan, which is a 27.71% increase year-on-year, and a net profit of 240 million yuan, up 42.11% year-on-year [2] - The company has a debt ratio of 33.87% and reported investment income of 33.23 million yuan, with financial expenses of -2.036 million yuan and a gross profit margin of 48.32% [2] - Over the past 90 days, 17 institutions have rated the stock, with 14 buy ratings and 3 hold ratings, and the average target price set by institutions is 5.488 billion yuan [2]

Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Steady Medical (300888) as of January 23, 2026, showing a stock price increase of 1.4% to 36.94 yuan with a trading volume of 5.08 million shares and a total transaction value of 1.87 billion yuan [1][2] - In the recent five days, the company reported a main revenue of 7.897 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 30.1%, and a net profit attributable to shareholders of 732 million yuan, up 32.36% year-on-year [2] - The company’s third-quarter performance for 2025 showed a single-quarter revenue of 2.601 billion yuan, a 27.71% increase year-on-year, and a net profit of 240 million yuan, which is a 42.11% increase year-on-year [2] Group 2 - The company has a debt ratio of 33.87% and reported investment income of 33.23 million yuan, with financial expenses of -2.036 million yuan and a gross profit margin of 48.32% [2] - Over the past 90 days, 22 institutions have rated the stock, with 18 buy ratings and 4 hold ratings, and the average target price set by institutions is 54.88 yuan [2]

Core Viewpoint - The stock of Steady Medical (300888) has experienced a decline, with a closing price of 38.08 yuan on January 15, 2026, down 3.57% from the previous day, indicating a potential shift in investor sentiment and market dynamics [1]. Financial Performance - For the first three quarters of 2025, Steady Medical reported a main revenue of 7.897 billion yuan, a year-on-year increase of 30.1% [3]. - The net profit attributable to shareholders was 732 million yuan, up 32.36% year-on-year, while the net profit excluding non-recurring items reached 679 million yuan, reflecting a 43.93% increase [3]. - In Q3 2025 alone, the company achieved a main revenue of 2.601 billion yuan, a 27.71% increase year-on-year, and a net profit of 240 million yuan, up 42.11% year-on-year [3]. Market Position - Steady Medical's total market capitalization stands at 22.175 billion yuan, ranking 4th in the beauty and personal care industry, which has an average market cap of 10.475 billion yuan [3]. - The company has a net asset value of 12.263 billion yuan, significantly higher than the industry average of 3.361 billion yuan, ranking 1st in the industry [3]. - The company's price-to-earnings ratio (P/E) is 22.72, which is lower than the industry average of 39.18, ranking 2nd in the industry [3]. Investment Sentiment - Over the past 90 days, 22 institutions have rated the stock, with 18 buy ratings and 4 hold ratings, indicating strong institutional interest [4]. - The average target price set by institutions for the stock is 54.88 yuan, suggesting potential upside from the current trading price [4]. Capital Flow Analysis - On January 15, 2026, the net inflow of main funds was 21.9313 million yuan, accounting for 5.01% of the total transaction amount, while retail investors saw a net outflow of 45.2048 million yuan, representing 10.34% of the total [1][2].

Group 1 - The core viewpoint of the news is that Steady Medical (300888) has shown significant growth in its financial performance, with a notable increase in revenue and net profit for the first three quarters of 2025 compared to the previous year [2] - As of January 14, 2026, Steady Medical's stock closed at 39.49 yuan, experiencing a slight decline of 0.23% with a trading volume of 79,100 hands and a total transaction amount of 314 million yuan [1] - The company reported a main business revenue of 7.897 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 30.1%, and a net profit attributable to shareholders of 732 million yuan, up 32.36% year-on-year [2] Group 2 - In the third quarter of 2025, Steady Medical achieved a single-quarter revenue of 2.601 billion yuan, which is a 27.71% increase year-on-year, and a net profit of 240 million yuan, marking a 42.11% increase year-on-year [2] - The company has a debt ratio of 33.87% and reported an investment income of 33.23 million yuan, with financial expenses of -2.036 million yuan and a gross profit margin of 48.32% [2] - Over the past 90 days, 22 institutions have rated the stock, with 18 buy ratings and 4 hold ratings, and the average target price set by institutions is 54.88 yuan [2]

Core Viewpoint - The company Steady Medical (300888) has shown significant growth in its financial performance, with a notable increase in revenue and net profit for the first three quarters of 2025 compared to the previous year [2]. Financial Performance - For the first three quarters of 2025, the company's main revenue reached 7.897 billion, reflecting a year-on-year increase of 30.1% [2]. - The net profit attributable to shareholders was 732 million, up 32.36% year-on-year [2]. - The net profit excluding non-recurring items was 679 million, marking a 43.93% increase year-on-year [2]. - In Q3 2025 alone, the company reported a single-quarter revenue of 2.601 billion, which is a 27.71% increase compared to the same quarter last year [2]. - The single-quarter net profit attributable to shareholders was 240 million, showing a year-on-year increase of 42.11% [2]. - The single-quarter net profit excluding non-recurring items was 218 million, reflecting a 50.77% increase year-on-year [2]. - The company's debt ratio stands at 33.87%, with investment income of 33.23 million and financial expenses of -2.036 million [2]. - The gross profit margin is reported at 48.32% [2]. Market Activity - As of January 12, 2026, the stock price closed at 39.73, with an increase of 1.43% [1]. - The trading volume was 59,800 hands, with a total transaction amount of 236 million [1]. - The net outflow of main funds was 2.9322 million, accounting for 1.24% of the total transaction amount [1]. - Retail investors showed a net inflow of 3 million, representing 1.27% of the total transaction amount [1]. Analyst Ratings - In the last 90 days, 22 institutions have provided ratings for the stock, with 18 buy ratings and 4 hold ratings [2]. - The average target price set by institutions over the past 90 days is 5.488 billion [2].